[Clinical trial of tiapride in patients with dyskinesia (author's transl)].

Abstract

Twenty-five patients with various forms of dyskinesia were given tiapride for three months. Maximal dosage was 900 mg per day. A double-blind trial of tiapride versus placebo showed significantly better results in the group given tiapride. The forms of dyskinesia which responded best to tiapride were the following: iatrogenic dyskinesia, tics (Gilles de la Tourette syndrome), and chronic chorea (Huntington disease). Patients with complex dyskinesia resulting from neonatal encephalopathy or vascular disease were not improved. The protocol used in l-dopa-induced dyskinesia is described. Changes in dyskinesia and "on-off" effect following variations in tiapride and l-dopa dosage are detailed. An unequivocal, although minor, tiapride-induced parkinson syndrome was recorded in a few patients. No instances of tiapride-induced dyskinesia or akathisia were seen. The other side-effects were either psychic (depression, drowsiness, agitation) or endocrinologic (menstrual disorders, overeating, galactorrhea).

• Authors: C Chouza, S Romero, J Lorenzo, J L Camano, A P Fontana, P Alterwain, D Cibils, J Gaudiano, S Feres, J Solana
• Journal: La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris (Sem Hop) Vol. 58 Issue 12 Pg. 725-33 (Mar 25 1982) France
• Vernacular Title: Traitement des dyskinésies par le tiapride.
• PMID: 6283645 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Benzamides
• Tiapamil Hydrochloride

Topics

• Adolescent
• Adult
• Aged
• Basal Ganglia Diseases (chemically induced)
• Benzamides (therapeutic use)
• Chemical Phenomena
• Chemistry
• Child
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Movement Disorders (drug therapy)
• Tiapamil Hydrochloride (adverse effects, therapeutic use)